|
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
<i>FoxD2-AS1</i> is a prognostic factor in glioma and promotes temozolomide resistance in a O<sup>6</sup>-methylguanine-DNA methyltransferase-dependent manner.
|
31680769 |
2019 |
|
Glioma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
<i>O</i>(6)-methylguanine-DNA-methyltransferase (MGMT) promoter methylation is a high predictive factor for therapy results of temozolomide in patients with glioma.
|
31422371 |
2020 |
|
Glioma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
(11)C-methionine PET could be a useful tool to detect MGMT promoter methylation in nonenhancing glioma.
|
25178915 |
2014 |
|
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Glioma cells rich in miR-181b were more sensitive to temozolomide. miR-181b expression was not correlated with MGMT promoter methylation status. miR-181b combined with temozolomide enhanced glioma cell sensitivity and apoptosis.
|
23645289 |
2013 |
|
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Glioma therapeutic resistance to alkylating chemotherapy is mediated via O6-methylguanine-DNA methyltransferase (MGMT).
|
30500933 |
2019 |
|
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
MGMT expression correlated exclusively with ACNU resistance in all glioma cell lines examined (p = 0.0002).
|
10678554 |
1999 |
|
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
O6-Methylguanine-DNA methyltransferase (MGMT), a DNA repair protein, is one of the implicated factors in glioma chemoresistance.
|
16033832 |
2005 |
|
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
MGMT promoter methylation and low expression of MGMT-encoded protein are frequently observed in low-grade gliomas and anaplastic oligodendroglial tumours.
|
17906460 |
2007 |
|
Glioma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR.
|
22390413 |
2012 |
|
Glioma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
MGMT (O(6)-methylguanine-DNA methyltransferase) controls DNA repair pathways, and its epigenetic silencing is used for predicting the response to the alkylating drug temozolomide in patients with glioma.
|
24709436 |
2014 |
|
Glioma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
MGMT promoter methylation represents a favorable prognostic factor and has been associated with a better response to alkylating agents in glioma and systemic lymphoma.
|
25031012 |
2014 |
|
Glioma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
MGMT methylation is a marker for poor prognosis in human glioma, while, MGMT methylation is a sensitive marker of glioma cells to alkylating agents.
|
26967246 |
2016 |
|
Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
MGMT gene variants, temozolomide myelotoxicity and glioma risk. A concise literature survey including an illustrative case.
|
28436299 |
2017 |
|
Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
MGMT CpG heterogeneity was investigated in 213 glioma patients in two tested cohorts: cohort A in which CpGs 75-82 were tested and cohort B in which CpGs 72-78 were tested.
|
30291347 |
2019 |
|
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
A novel approach to overcome temozolomide resistance in glioma and melanoma: Inactivation of MGMT by gene therapy.
|
21329652 |
2011 |
|
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
A previous study using the RNA microarray technique showed that decrease of MGMT mRNA stands out among the alterations in gene expression caused by the cell growth-depressing transfection of a T98G glioma cell line with liver-type glutaminase (LGA) [Szeliga et al.(2009) Glia, 57, 1014].
|
22888977 |
2012 |
|
Glioma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
A simplified laboratory validated assay for MGMT promoter hypermethylation analysis of glioma specimens from formalin-fixed paraffin-embedded tissue.
|
17260000 |
2007 |
|
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Accordingly, we also examined whether the MGMT status determines glioma cell responses to cilengitide alone or in combination with temozolomide.
|
19221171 |
2009 |
|
Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Activated leukocyte adhesion molecule expression in gliomas was independent of proliferative activity, MGMT status, patient survival, and age, whereas gliomas with IDH1 (R132H) mutation had significantly higher activated leukocyte adhesion molecule levels than their wild-type counterparts.
|
22304788 |
2012 |
|
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Active MGMT might have a protective role in LGG tumors, enabling evolution to severe malignancy.
|
28575062 |
2017 |
|
Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Algorithms have been developed to detect the glioma CpG island methylator phenotype (G-CIMP) associated with IDH1/2 mutation, 1p/19q codeletion, and MGMT promoter methylation using a single assay.
|
25028501 |
2014 |
|
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although methylguanine-DNA-methyltransferase (MGMT) plays an important role in resistance to temozolomide (TMZ) in glioma, 40% of gliomas with MGMT inactivation are still resistant to TMZ.The underlying mechanism is not clear.
|
28185110 |
2017 |
|
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
APTw characteristics could be promising imaging markers by which to predict IHC MGMT expression in primary low- and high-grade gliomas preoperatively and noninvasively.
|
29803064 |
2018 |
|
Glioma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Assessing the predictability of IDH mutation and MGMT methylation status in glioma patients using relaxation-compensated multipool CEST MRI at 7.0 T.
|
29733378 |
2018 |
|
Glioma
|
0.400 |
Biomarker
|
disease |
LHGDN |
Assessment of MGMTP status could help identifying low-grade gliomas patients more likely to respond to chemotherapy or to benefit from MGMT depletion strategies.
|
17192931 |
2006 |